Skip to content
10-Q

Quarterly Report

Cogent Biosciences, Inc. COGT

0001193125-26-205170

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 170.87M sh
Shares Diluted Q1 2026 · Mar 31, 2026 162.19M sh
Shares Diluted Q1 2026 · Mar 31, 2025 113.31M sh
Capex Q1 2026 · Mar 31, 2026 $449K
Capex Q1 2026 · Mar 31, 2025 $547K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$86.88M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$66.51M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $241.21M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $312.01M
Stockholders Equity Q1 2026 · Mar 31, 2026 $607.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 $636.37M
Stockholders Equity Q1 2026 · Mar 31, 2025 $219M
Stockholders Equity Q1 2026 · Dec 31, 2024 $256.29M
Current Liabilities Q1 2026 · Mar 31, 2026 $57.98M
Current Liabilities Q1 2026 · Dec 31, 2025 $63.95M
Total Liabilities Q1 2026 · Mar 31, 2026 $295.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $301.24M
Current Assets Q1 2026 · Mar 31, 2026 $877.8M
Current Assets Q1 2026 · Dec 31, 2025 $910.36M
Total Assets Q1 2026 · Mar 31, 2026 $903.01M
Total Assets Q1 2026 · Dec 31, 2025 $937.61M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.53
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.52
Eps Basic Q1 2026 · Mar 31, 2026 −$0.53
Eps Basic Q1 2026 · Mar 31, 2025 −$0.52
Sga Expense Q1 2026 · Mar 31, 2026 $28.24M
Sga Expense Q1 2026 · Mar 31, 2025 $11.9M
Rd Expense Q1 2026 · Mar 31, 2026 $75.37M
Rd Expense Q1 2026 · Mar 31, 2025 $63.03M
Net Income Q1 2026 · Mar 31, 2026 −$97.35M
Net Income Q1 2026 · Mar 31, 2025 −$71.99M
Operating Income Q1 2026 · Mar 31, 2026 −$103.61M
Operating Income Q1 2026 · Mar 31, 2025 −$74.93M